FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:905-917 March 3, 2005 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Antithyroid drugs, which have been in use for more than half a century, remain cornerstones in the management of hyperthyroidism, especially for patients with Graves' disease. Surveys of thyroidologists from the early 1990s indicate that most practitioners consider antithyroid drugs the treatment of choice for most young people with Graves' disease, both in the United States and in the rest of the world.^1,2 A substantial amount of new information, much of it evidence-based,³ has become available since the topic was last summarized in the Journal in 1984.⁴ The present review considers recent pharmacologic and clinical data related to the use . . . [Full Text of this Article]

Pharmacology

Mechanism of Action

Clinical Pharmacology

Clinical Use of Drugs

Choice of Drugs

Practical Considerations

Remission

Discontinuation of Drug Treatment

Side Effects

Use of Antithyroid Drugs during Pregnancy and Lactation

Thyroid Storm

Summary

Source Information

From the Division of Endocrinology, Sinai Hospital of Baltimore, the Johns Hopkins University School of Medicine, Baltimore.

Address reprint requests to Dr. Cooper at the Division of Endocrinology, Sinai Hospital of Baltimore, 2401 W. Belvedere Ave., Baltimore, MD 21215, or at dcooper@lifebridgehealth.org.

Related Letters:

Antithyroid Drugs
Goichot B., Vinzio S., Lubin E., Nebesio T. D., Eugster E. A., Admiraal P. J.J., Cooper D. S.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:2246-2247, May 26, 2005. Correspondence

This article has been cited by other articles:

• Gao, Y., Chen, M., Ye, H., Yu, F., Guo, X.-h., Zhao, M.-h. (2008). Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxford) 0: ken321v1-ken321 [Abstract] [Full Text]  
• Hernandez, M. I., Lee, K.-W. (2008). Neonatal Graves Disease Caused by Transplacental Antibodies. NeoReviews 9: e305-e309 [Abstract] [Full Text]  
• Brent, G. A. (2008). Graves' Disease. NEJM 358: 2594-2605 [Full Text]  
• Biondi, B., Cooper, D. S. (2008). The Clinical Significance of Subclinical Thyroid Dysfunction. Endocr. Rev. 29: 76-131 [Abstract] [Full Text]  
• Li, H., Richard, K., McKinnon, B., Mortimer, R. H. (2007). Effect of Iodide on Human Choriogonadotropin, Sodium-Iodide Symporter Expression, and Iodide Uptake in BeWo Choriocarcinoma Cells. J. Clin. Endocrinol. Metab. 92: 4046-4051 [Abstract] [Full Text]  
• Inukai, Y., Momobayashi, A., Sugawara, N., Aso, Y. (2007). Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol 156: 623-630 [Abstract] [Full Text]  
• Schmutzler, C., Bacinski, A., Gotthardt, I., Huhne, K., Ambrugger, P., Klammer, H., Schlecht, C., Hoang-Vu, C., Gruters, A., Wuttke, W., Jarry, H., Kohrle, J. (2007). The Ultraviolet Filter Benzophenone 2 Interferes with the Thyroid Hormone Axis in Rats and Is a Potent in Vitro Inhibitor of Human Recombinant Thyroid Peroxidase. Endocrinology 148: 2835-2844 [Abstract] [Full Text]  
• Chattaway, J. M, Klepser, T. B (2007). Propylthiouracil Versus Methimazole in Treatment of Graves' Disease During Pregnancy. The Annals of Pharmacotherapy 41: 1018-1022 [Abstract] [Full Text]  
• El Fassi, D., Nielsen, C. H., Bonnema, S. J., Hasselbalch, H. C., Hegedus, L. (2007). B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves' Disease: A Controlled Pilot Study. J. Clin. Endocrinol. Metab. 92: 1769-1772 [Abstract] [Full Text]  
• Walter, M. A, Briel, M., Christ-Crain, M., Bonnema, S. J, Connell, J., Cooper, D. S, Bucher, H. C, Muller-Brand, J., Muller, B. (2007). Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 334: 514-514 [Abstract] [Full Text]  
• Rivkees, S. A., Dinauer, C. (2007). An Optimal Treatment for Pediatric Graves' Disease Is Radioiodine. J. Clin. Endocrinol. Metab. 92: 797-800 [Abstract] [Full Text]  
• Iagaru, A., McDougall, I. R. (2007). Treatment of Thyrotoxicosis. JNM 48: 379-389 [Abstract] [Full Text]  
• Moriyama, K., Tagami, T., Usui, T., Naruse, M., Nambu, T., Hataya, Y., Kanamoto, N., Li, Y.-s., Yasoda, A., Arai, H., Nakao, K. (2007). Antithyroid Drugs Inhibit Thyroid Hormone Receptor-Mediated Transcription. J. Clin. Endocrinol. Metab. 92: 1066-1072 [Abstract] [Full Text]  
• Vilchez, F. J, Torres, I., Garcia-Valero, A., Lopez-Tinoco, C., de los Santos, A., Aguilar-Diosdado, M. (2006). Concomitant Agranulocytosis and Hepatotoxicity After Treatment with Carbimazole. The Annals of Pharmacotherapy 40: 2059-2063 [Abstract] [Full Text]  
• Premawardhana, L D K E, Lazarus, J H (2006). Management of thyroid disorders.. Postgrad. Med. J. 82: 552-558 [Abstract] [Full Text]  
• Varughese, G. I., Tahrani, A. A., Smith, J. L., Clayton, R. N., Hanna, F. W. (2006). Carbimazole therapy in the setting of end-stage renal disease and haemodialysis. Nephrol Dial Transplant 21: 2318-2319 [Full Text]  
• Bonnema, S. J., Bennedbaek, F. N., Veje, A., Marving, J., Hegedus, L. (2006). Continuous Methimazole Therapy and Its Effect on the Cure Rate of Hyperthyroidism Using Radioactive Iodine: An Evaluation by a Randomized Trial. J. Clin. Endocrinol. Metab. 91: 2946-2951 [Abstract] [Full Text]  
• Pearce, E. N (2006). Diagnosis and management of thyrotoxicosis.. BMJ 332: 1369-1373 [Full Text]  
• Razvi, S., Vaidya, B., Perros, P., Pearce, S. H S (2006). What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease.. Eur J Endocrinol 154: 783-786 [Abstract] [Full Text]  
• El Fassi, D., Nielsen, C. H, Hasselbalch, H. C, Hegedus, L. (2006). The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.. Eur J Endocrinol 154: 623-632 [Abstract] [Full Text]  
• Coco, G., Dal Pra, C., Presotto, F., Albergoni, M. P., Canova, C., Pedini, B., Zanchetta, R., Chen, S., Furmaniak, J., Rees Smith, B., Mantero, F., Betterle, C. (2006). Estimated Risk for Developing Autoimmune Addison's Disease in Patients with Adrenal Cortex Autoantibodies. J. Clin. Endocrinol. Metab. 91: 1637-1645 [Abstract] [Full Text]  
• Goichot, B., Vinzio, S., Lubin, E., Nebesio, T. D., Eugster, E. A., Admiraal, P. J.J., Cooper, D. S. (2005). Antithyroid Drugs. NEJM 352: 2246-2247 [Full Text]